News

BD Medical – Ophthalmic Systems, a unit of BD, has an exclusive worldwide license from HyperBranch to market OcuSeal for use in ophthalmology. It will immediately begin to

The Partner trial is a randomized, controlled, multi-center study that assigns patients into one of two arms: a ‘non-surgical’ arm, in which the Edwards’s Sapien valve is compared

Mr Wallwork will also be chairing the company’s scientific advisory board where his knowledge and background in pulmonary hypertension as well as his experience in the management of

The alliance provides clinical trial sponsors direct access to the world’s most experienced team of thorough QT scientists, unparalleled subject enrollment and bed capacity, integrated study management and

In conjunction with this financing, Anders Hove of Venrock Associates and Myles Greenberg of CHL Medical Partners will join Still River Systems’s board of directors. Still River Systems

The ImCardia is an elastic device placed on the outer surface of the left ventricle. A breakthrough preclinical study has shown the ImCardia to harness elastic energy produced

Year-to-date, nine-month revenues rose 17% in the current fiscal year to $87,831,000 from FY 2008’s $75,299,000. Year-to-date net income for the first nine months of Neogen’s 2009 fiscal

“We are delighted about Linda’s decision to join Arbor Vita at this time,” commented Peter S. Lu, founder, president and chief executive officer. “Linda brings to AVC an

Roche has signed a definitive agreement with innovatis, a provider of automated cell analysis solutions, pursuant to which, Roche will acquire 100% of innovatis for E15m. This acquisition